The Altman Z-Score is a model designed to predict the likelihood of a company going bankrupt within the next two years. Created by American finance professor Edward Altman in 1968, the model is specifically designed for publicly traded manufacturing companies with assets greater than $1 million.
Warning Sign:
Altman Z-score of -19.21 is in distress zone. This implies bankruptcy possibility in the next two years.
Lyra Therapeutics has a Altman Z-Score of -19.21, indicating it is in Distress Zones. This implies bankrupcy possibility in the next two years.
The zones of discrimination were as such:
When Altman Z-Score <= 1.8, it is in Distress Zones.
When Altman Z-Score >= 3, it is in Safe Zones.
When Altman Z-Score is between 1.8 and 3, it is in Grey Zones.
The historical rank and industry rank for Lyra Therapeutics's Altman Z-Score or its related term are showing as below:
LYRA'
s Altman Z-Score Range Over the Past 10 Years
Min: -19.21 Med: -5.24 Max: -0.4
Current: -19.21
During the past 8 years, Lyra Therapeutics's highest Altman Z-Score was -0.40. The lowest was -19.21. And the median was -5.24.
X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.
X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.
X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.
X4, Market Value of Equity/Book Value of Total Liabilities (MVE/TL): The measure shows how much the firm's assets can decline in value (measured by market value of equity plus debt) before the liabilities exceed the assets and the firm becomes insolvent.
X5, Revenue/Total Assets (S/TA): The capital-turnover ratio is a standard financial ratio illustrating the sales generating ability of the firm's assets.
Altman Z-Score does not apply to financial companies.
Lyra Therapeutics Altman Z-Score Related Terms
Lyra Therapeutics Altman Z-Score Historical Data
* Premium members only.
The historical data trend for Lyra Therapeutics's Altman Z-Score can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LYRA vs EVFM, CLSDQ, ATXI: Altman Z-Score Comparison
For the Biotechnology subindustry, Lyra Therapeutics's Altman Z-Score, along with its competitors' market caps and Altman Z-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lyra Therapeutics Altman Z-Score vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Lyra Therapeutics's Altman Z-Score distribution charts can be found below:
* The bar in red indicates where Lyra Therapeutics's Altman Z-Score falls into.
Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.
Lyra Therapeutics's Altman Z-Score for today is calculated with this formula:
Z
=
1.2
*
X1
+
1.4
*
X2
+
3.3
*
X3
+
0.6
*
X4
+
1.0
*
X5
=
1.2
*
0.1869
+
1.4
*
-12.0114
+
3.3
*
-0.8006
+
0.6
*
0.0269
+
1.0
*
0.011
=
-19.21
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z-Score when X4 or X5 value is 0.
Lyra Therapeutics (LYRA) has a Altman Z-Score of -19.21 as of Jul. 05, 2026. The Altman Z-score measures a company's bankruptcy risk. View historical data on Lyra Therapeutics and its competitors. According to the industry distribution chart, Lyra Therapeutics ranks #857 out of 926 companies in the Biotechnology industry, placing it in the top 92.5%.
Is Lyra Therapeutics' Altman Z-Score too high?
Lyra Therapeutics' current Altman Z-Score is -19.21. Based on the distribution chart, Lyra Therapeutics ranks #857 out of 926 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Lyra Therapeutics has a GF Score™ of 25/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Lyra Therapeutics' Altman Z-Score compare to EVFM and CLSDQ?
According to the Biotechnology industry distribution chart, Lyra Therapeutics ranks #857 out of 926 companies for Altman Z-Score. This places Lyra Therapeutics in the lower half of its industry. The industry median Altman Z-Score is 2.77. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Altman Z-Score for a Biotechnology company?
The median Altman Z-Score among Biotechnology companies is 2.77, based on 926 companies in the industry. Companies in the top quartile (top 25%) have a Altman Z-Score significantly above this median, while those in the bottom quartile fall well below. However, Altman Z-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Altman Z-Score mean?
A high Altman Z-Score can signal that a stock is expensive relative to its fundamentals. The Altman Z-score measures a company's bankruptcy risk. View historical data on Lyra Therapeutics and its competitors. For the Biotechnology industry, the median Altman Z-Score is 2.77 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lyra Therapeutics's current Altman Z-Score is -19.21. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lyra Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Lyra Therapeutics (LYRA) is currently considered Possible Value Trap. The stock's GF Value™ is $2.54, compared to a current price of $0.71 — trading 72.1% below its estimated fair value. The current Altman Z-Score is -19.21. Lyra Therapeutics' overall GF Score™ is 25/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Altman Z-Score calculated?
Altman Z-Score is calculated from a company's financial statements. For Lyra Therapeutics (LYRA), the current Altman Z-Score is -19.21 as of Jul. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Lyra Therapeutics (LYRA) Overvalued in 2026?
Based on GuruFocus' analysis, Lyra Therapeutics stock appears to be undervalued.
The current stock price of $0.71 is trading 72.1% below its estimated GF Value™ of $2.54.
GuruFocus considers Lyra Therapeutics to be Possible Value Trap.
Key valuation signals for LYRA:
Altman Z-Score: -19.21
GF Value™: $2.54 vs. price of $0.71 (72.1% below fair value)
No single metric tells the full story. See the LYRA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Lyra Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of anti-inflammatory therapies for the localized treatment of patients with chronic rhinosinusitis, or CRS. Its products include LYR-210 and LYR-220. The company operates in a single operating segment, which is the business of developing targeted medicines to address ear, nose, and throat, or ENT, diseases.
25GF Score
Get the complete analysis for LYRA
Altman Z-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LYRA has been successfully added to your 
